Devgen launches its nematicide in the US under the brand name Enclosure®
(Thomson Reuters ONE) -
Devgen US Inc. today announced the launch of the Enclosure(® )nematicide in the
U.S. for use in commercial peanut production.
The U.S. annually produces around 1.8 million tons of peanuts on 1.2 million
acres (500,000 hectares). This makes the U.S. the third largest producer of
peanuts in the world and one of the world's leading peanut exporters, with an
average annual export between 200,000 to 250,000 tons.
Devgen's initial target markets for Enclosure(® )are Georgia, Alabama and
Florida, which account for approximately 57% of all peanuts grown in the U.S.
Root-knot nematodes and soil-borne diseases[1] cost peanut growers millions of
dollars in yield losses. The dual activity of Enclosure(®) allows farmers to
manage several pathogens that reduce quality and yield. Enclosure(®) suppresses
the most serious root-knot nematode pest, Meloidogyne arenaria, as well as other
nematode species. Enclosure(®) also suppresses Sclerotinia blight (Sclerotinia
minor) and peg & pod rot (Rhizoctonia solani).
Devgen is pleased to provide the peanut grower with a new solution to suppress
nematodes, as well as soil-borne diseases, in an environment where the choice of
products is becoming increasingly limited. Enclosure(® )also offers advantages
from a toxicological, environmental, residue and worker exposure point of view.
The product will be distributed by Helena Chemical Company, a leading supplier
of crop protection products and services in the U.S.
For more information please contact:
Thierry Bogaert, CEO
Thierry.Bogaert(at)devgen.com
About Devgen Company
DEVGEN US Inc. is a subsidiary of Devgen nv (Euronext Brussels: DEVG), a global
provider of technology-based solutions and agricultural products. To learn more
about our business and our commitments, please visit: www.devgen.com
Cautionary Statements Regarding Forward-Looking Information:
Certain statements contained in this press release are forward-looking
statements, such as statements concerning the company's future product
performance, regulatory approvals, business and financial plans and other
non-historical facts. These statements are based on current expectations and
currently available information. However, since these statements are based on
factors that involve risks and uncertainties, the company's actual performance
and results may differ materially from those described or implied by such
forward-looking statements. Factors that could cause or contribute to such
differences include, among others: the success of the company's research and
development activities; agricultural risks and difficulties, including weather
factors, diseases and pests; ; the costs and requirements of regulatory
compliance and the speed with which approvals are received; public acceptance of
biotechnology products; political, economic and social developments in countries
where Devgen operates and other risks and factors detailed in the company's most
recent periodic public reports. Undue reliance should not be placed on these
forward-looking statements, which are current only as of the date of this
release. The company disclaims any current intention or obligation to update any
forward-looking statements or any of the factors that may affect actual results.
--------------------------------------------------------------------------------
[1] The diseases that are caused by fungal pathogens which persist (survive) in
the soil matrix and in residues on the soil surface are defined as soil-borne
diseases."
[HUG#1417362]
PR ENG: http://hugin.info/135721/R/1417362/367789.pdf
Unternehmensinformation / Kurzprofil:
Datum: 19.05.2010 - 19:00 Uhr
Sprache: Deutsch
News-ID 21178
Anzahl Zeichen: 0
contact information:
Town:
Gent-Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 250 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Devgen launches its nematicide in the US under the brand name Enclosure®"
steht unter der journalistisch-redaktionellen Verantwortung von
Devgen (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
